Saint-Joseph University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Philadelphia PA United States (1851)

Organization Overview

First Clinical Trial
2003
NCT00610623
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Centre Hospitalier Saint-Joseph-PARIS | General Intensive Care Unit, Hospital Saint-Joseph, Paris, France | Hospital Saint-Joseph, Paris, France | Ogarite Habib | Saint-Joseph University | Saint Joseph University- Lebanon | Saint Joseph University School of Medicine | Saint JU | Yara El Helou

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 4)

Anemia, Iron-Deficiency (Phase 4)

Atrial Fibrillation (Phase 4)

Calcinosis (Phase 4)

Colorectal Neoplasms (Phase 2)

Coronary Artery Disease (Phase 4)

Dandruff (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Dyslipidemias (Phase 2)

Hyperlipidemias (Phase 2)

Hyperlipoproteinemias (Phase 2)

Labor Pain (Phase 4)

Mental Disorders (Phase 3)

Neoplasm Metastasis (Phase 2)

Pain, Postoperative (Phase 4)

Pityriasis (Phase 3)

Pityriasis Rosea (Phase 3)

Pneumonia (Phase 2)

Pneumonia, Ventilator-Associated (Phase 2)

Pseudomonas Infections (Phase 2)

Psychotic Disorders (Phase 3)

Sleep Deprivation (Phase 3)

Vascular Calcification (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 35